NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...